Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.65 |
| ▸ | CNR2 | P34972 | 4/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122027 | 0.88 | PTGDR2 (0.75) | PTGDR2CYP2C9PTGER2PTGDRSIRT2 | |
| SCHEMBL601773 | 0.86 | AKR1B10 (0.64) | PTGDR2CNR2CNR1AKR1B10AKR1B1 | |
| SCHEMBL3073539 | 0.79 | PTGDR2 (1.00) | PTGDR2CYP2C9AKR1B10AKR1B1PTGER2 | |
| SCHEMBL601140 | 0.78 | PTGDR2 (0.53) | PTGDR2CYP2C9DRD4AKR1B10AKR1B1 | |
| SCHEMBL3087327 | 0.76 | PTGDR2 (0.80) | PTGDR2CYP2C9AKR1B10AKR1B1PTGER2 | |
| SCHEMBL600037 | 0.74 | AKR1B10 (0.70) | PTGDR2AKR1B10AKR1B1MAOAMAOB | |
| SCHEMBL3094109 | 0.73 | PTGDR2 (1.00) | PTGDR2CYP2C9PTGER2PTGDR | |
| SCHEMBL3090842 | 0.73 | PTGDR2 (0.75) | PTGDR2CYP2C9AKR1B10AKR1B1PTGER2 | |
| SCHEMBL602544 | 0.72 | SIRT2 (0.55) | CNR2CNR1MAOAMAOBPDE5A | |
| SCHEMBL3077017 | 0.71 | PTGDR2 (0.84) | PTGDR2CYP2C9PTGER2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | claimed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | claimed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PTGDR2 110/4885CNR2 2/4885CNR1 1/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PTGDR2 110/4885CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.